As a progressive chronic disease, age-related macular degeneration (AMD) is the leading
cause of irreversible vision impairment worldwide. Experimental and clinical evidence has …

Retinal angiomatous proliferation (RAP), recently termed “type 3 neovascularization,”
represents a distinct form of neovascularization in age-related macular degeneration. On the …

The introduction of intravitreal antivascular endo-thelial growth factor (VEGF) therapy for
neovascular age-related macular degeneration (AMD) has not only improved the quality of …

Background: Retinal angiomatous proliferation (RAP) is a distinct form of neovascularization
in patients with age-related macular degeneration. Lacking definitive sequential …

Purpose: The purpose of this study was to analyze long-term outcomes for the treatment of
type 3 neovascularization/retinal angiomatous proliferation using a “Treat and Extend” …

Purpose: The purpose of this study was to compare two strategies for retreatment with
ranibizumab in exudative age-related macular degeneration. Method: Two series of …

Retinal angiomatous proliferation (RAP) is a unique variant of neovascular age-related
macular degeneration. Published studies have estimated that up to 15% of patients with …

Purpose: To investigate the natural history and visual outcome in eyes with untreated retinal
angiomatous proliferation, a neovascular form of age-related macular degeneration …

Triamcinolone acetonide (TA) is one of the first pharmacologic compounds evaluated for the
treatment of choroidal neovascularization (CNV) secondary to age-related macular …

Objective: To evaluate the short-term visual acuity and anatomic responses after intravitreal
bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous …